Acute Cholangitis: Causes, Symptoms, Diagnosis, and Treatment

What Is Acute Cholangitis?

Acute cholangitis, also called ascending cholangitis, is a potentially life-threatening condition caused by bacterial infection of the bile ducts (the biliary system). The term “ascending” reflects the mechanism by which the infection typically reaches the biliary system: bacteria ascend from the duodenum (the first segment of the small intestine) into the bile duct, facilitated by obstruction that impairs the normal downward flow of bile and the biliary system’s natural antimicrobial defenses.

The biliary system, which connects the liver, gallbladder, and small intestine, is responsible for producing, storing, and transporting bile, a digestive fluid essential for the absorption of dietary fats and fat-soluble vitamins. When this system is obstructed, most commonly by gallstones, the resulting increase in biliary pressure and stasis creates an environment where bacteria can rapidly multiply. This can lead to biliary infection and its potentially devastating systemic consequences.

Acute cholangitis classically presents with the triad of symptoms first described by the French neurologist Jean-Martin Charcot in 1877. This is now known as Charcot’s triad:

1. Fever (and chills)
2. Jaundice (yellow discoloration of the skin and whites of the eyes)
3. Abdominal pain (typically in the right upper quadrant)

Diagnosis is primarily clinical, based on the recognition of this symptom triad in the appropriate clinical context, and is confirmed by laboratory tests and imaging studies that demonstrate infection and biliary obstruction.

Initial medical management centers on intravenous fluids and antibiotics, and must be initiated promptly. Delay in treatment significantly worsens outcomes, with the risk of progression to septic shock (a life-threatening systemic response to infection) being a constant concern in inadequately managed cases. When biliary obstruction does not resolve with antibiotics alone, biliary drainage (via endoscopic or surgical techniques) is required.

With appropriate and timely management, acute cholangitis is a treatable condition with excellent outcomes in most patients. However, prognosis deteriorates significantly with delayed treatment, advanced age, underlying comorbidities, and the development of multiorgan dysfunction.

Distinguishing Acute Cholangitis from Other Biliary Conditions

Acute cholangitis should be carefully distinguished from several other chronic or autoimmune conditions that can also affect the bile ducts, including:

• Primary biliary cholangitis (PBC) (also called primary biliary cirrhosis): An autoimmune disease causing chronic inflammation and progressive destruction of the small intrahepatic bile ducts, unrelated to bacterial infection.
• IgG4-related sclerosing cholangitis: A fibroinflammatory condition associated with elevated serum IgG4 levels, belonging to the spectrum of IgG4-related disease.
• Primary sclerosing cholangitis (PSC): A chronic progressive cholestatic liver disease of unknown etiology causing multifocal stricturing of the biliary tree.

These chronic conditions are pathophysiologically and clinically distinct from acute cholangitis and require entirely different management approaches.

---

Causes and Risk Factors

The Pathophysiology of Biliary Infection

To understand why acute cholangitis develops, it is helpful to understand the normal physiology of the biliary system. Bile, a fluid produced by the liver, flows continuously from the liver through a series of progressively larger bile ducts. It is concentrated and temporarily stored in the gallbladder, and is released into the duodenum in response to a meal to facilitate fat digestion and absorption.

Under normal conditions, the biliary system maintains sterility through several mechanisms:

• The continuous downward flow of bile washes microorganisms away from the bile ducts and toward the intestine
• Bile itself has some antimicrobial properties (bile salts are toxic to many bacteria)
• The sphincter of Oddi, a muscular valve at the junction of the bile duct and duodenum, prevents retrograde migration of intestinal bacteria into the bile duct.
• Biliary immunoglobulin A (IgA) provides local immune defense

When biliary obstruction occurs, these defense mechanisms are compromised simultaneously:

1. Bile flow slows or stops, eliminating the mechanical flushing effect
2. Biliary pressure rises, impairing bile production and IgA secretion by cholangiocytes (biliary epithelial cells)
3. The increased biliary pressure may cause temporary dysfunction of the sphincter of Oddi, allowing retrograde bacterial reflux from the duodenum

The result is rapid bacterial colonization of the bile ducts, followed by multiplication and toxin production. As biliary pressure continues to rise, bacteria and their endotoxins (particularly in gram-negative organisms) gain access to the portal venous system and hepatic lymphatics. This process, called biliovascular reflux, allows them to reach the systemic circulation, triggering systemic infection (bacteremia) and, if unchecked, sepsis and septic shock.

Primary Cause: Biliary Obstruction and Gallstones

Gallstones (cholelithiasis) are by far the most common cause of acute cholangitis, responsible for approximately 50–70% of cases in Western populations. Gallstones typically form in the gallbladder and may migrate into the common bile duct (a condition called choledocholithiasis), where they can cause partial or complete obstruction of bile flow. Even partial obstruction significantly impairs the biliary clearance mechanisms and predisposes to bacterial colonization and ascending infection.

The specific bacteria most commonly involved in biliary infections reflect the normal intestinal flora. The most frequent isolates include:

• Gram-negative enteric organisms: Escherichia coli (the most common, approximately 25–50% of cases), Klebsiella pneumoniae, Enterobacter species
• Gram-positive organisms: Enterococcus species
• Anaerobes: Bacteroides species and Clostridium species (more common in elderly patients, those with prior biliary surgery, and those with recurrent episodes)
• Mixed infections (involving multiple organisms) are common

Other Causes of Biliary Obstruction Leading to Cholangitis

While gallstones are the most common cause, numerous other conditions can obstruct bile flow and precipitate acute cholangitis:

• Malignant biliary obstruction: Cancers of the pancreas, bile duct (cholangiocarcinoma), ampulla of Vater, duodenum, or gallbladder can obstruct the biliary system, particularly at the distal common bile duct. Malignant obstruction is an important cause in older patients without prior gallstone disease.

• Iatrogenic strictures: Narrowing of the bile duct as a consequence of prior biliary surgery (including cholecystectomy, hepatic resection, or biliary reconstruction) or prior ERCP (post-sphincterotomy stricture). Patients who have undergone biliary surgery are at lifelong risk of developing biliary strictures that can predispose to recurrent cholangitis.

• Blood clots (hemobilia): Clotted blood within the biliary system, occurring as a complication of biliary procedures, liver biopsy, or hepatic trauma, can obstruct bile flow and cause cholangitis.

• Pancreatitis: Edematous swelling of the head of the pancreas can externally compress the distal common bile duct, causing biliary obstruction. Gallstone pancreatitis (in which a gallstone obstructs both the pancreatic duct and the common bile duct at their shared ampullary orifice) is a particularly important cause of combined pancreatitis and cholangitis.

• Biliary stent occlusion: Patients who have had biliary stents placed (for malignant or benign biliary obstruction) are at significant risk of stent occlusion due to biofilm formation and stone deposition within the stent lumen, causing recurrent cholangitis. This is a frequent cause of recurrent cholangitis in patients undergoing palliative management of biliary malignancy.

• Parasitic infections: In endemic regions of Southeast Asia, South Asia, and South America, hepatic parasitosis can cause biliary obstruction and cholangitis. Important parasitic causes include:

  • Ascariasis: Adult Ascaris lumbricoides worms can migrate from the duodenum into the bile duct, causing mechanical obstruction, biliary colic, and cholangitis.
  • Tapeworm (echinococcosis): Hepatic hydatid cysts can rupture into the biliary system, causing cholangitis from cyst contents.
  • Liver flukes (Clonorchis sinensis, Opisthorchis viverrini): Parasitic flatworms that inhabit the bile ducts, causing chronic biliary inflammation, stricturing, and predisposition to cholangitis and cholangiocarcinoma.

• Choledochal cysts: Congenital dilations of the bile duct system associated with bile stasis and recurrent cholangitis.

• Mirizzi syndrome: Mechanical compression of the common hepatic duct by a large gallstone impacted in the cystic duct or Hartmann’s pouch of the gallbladder.

Risk Factors for Developing Acute Cholangitis

The following factors increase an individual’s likelihood of developing acute cholangitis:

Acute cholangitis most commonly affects individuals between the ages of 50 and 60 years, with no significant difference in incidence between men and women.

---

Symptoms

The clinical presentation of acute cholangitis spans a wide spectrum of severity, from mild self-limited illness to rapidly progressive, life-threatening infection with multiorgan failure.

Charcot’s Triad

The classic presentation of acute cholangitis, described by Jean-Martin Charcot in 1877 and still a cornerstone of clinical diagnosis, is the simultaneous occurrence of:

1. Fever (typically above 38.5°C / 101.3°F) with rigors (severe shaking chills): Fever reflects the systemic response to biliary infection. The presence of rigors, which are episodes of intense, uncontrollable shivering, is particularly significant. They indicate bacteremia (bacteria in the bloodstream) and signal rapid systemic dissemination of the infection.

2. Jaundice (icterus): Yellowing of the skin, sclera (whites of the eyes), and mucous membranes from elevated serum bilirubin, resulting from impaired biliary excretion due to bile duct obstruction. The degree of jaundice varies with the severity and completeness of obstruction. Associated symptoms of biliary obstruction often include:

   • Generalized pruritus (itching): From bile salt accumulation in the skin
   • Light-colored (pale, clay-colored) stools: From reduced bilirubin delivery to the intestine
   • Dark urine: From renal excretion of accumulated bilirubin

3. Right upper quadrant abdominal pain: Typically described as a constant, dull-to-severe ache in the right upper abdomen, sometimes radiating to the right shoulder or back. The pain reflects distension of the bile duct and gallbladder from obstruction, and inflammation of the biliary epithelium.

Charcot’s triad is present in approximately 50–70% of patients with acute cholangitis, a lower proportion than might be expected. This reflects the variable and sometimes incomplete clinical presentation. The absence of one or more elements of the triad does not exclude the diagnosis.

Reynolds’ Pentad

In the most severe cases of acute cholangitis, the systemic infection progresses to septic shock and encephalopathy, producing Reynolds’ Pentad, which is Charcot’s triad plus:

4. Altered mental status / confusion: Reflecting cerebral hypoperfusion and/or the direct effect of septic encephalopathy. This can range from subtle confusion and disorientation to profound coma.

5. Hemodynamic instability (hypotension): Low blood pressure reflecting septic shock, a state of systemic inflammatory response with circulatory failure resulting from uncontrolled infection. Patients with hemodynamic instability require immediate intensive care unit (ICU) admission and aggressive resuscitation.

Reynolds’ Pentad is present in a minority of patients (approximately 5–10%) but indicates severe, potentially life-threatening disease requiring emergency intervention.

General Presentation

Beyond the classic triads, patients with acute cholangitis typically present as visibly unwell, with:

• Malaise and profound fatigue: Patients are often dramatically ill-appearing, unable to perform their normal activities.
• Nausea and vomiting: Common accompanying symptoms.
• Anorexia: Loss of appetite.
• Abdominal distension: From ileus (paralytic slowing of intestinal motility) associated with the systemic inflammatory response.
• Signs of dehydration: Dry mucous membranes, reduced skin turgor, tachycardia, and decreased urine output.

Variability in Clinical Presentation

It is important to emphasize that the clinical presentation of acute cholangitis is highly variable:

• Elderly patients and immunocompromised individuals may present with atypical features, such as minimal fever, subtle or absent jaundice, and predominant confusion or hypotension, making early clinical recognition more difficult.
• Patients with prior biliary surgery or endoscopy may develop cholangitis with a less typical picture due to altered anatomy.
• Mild cholangitis may present with low-grade fever, only mild jaundice, and modest abdominal discomfort. This presentation may initially seem reassuring but can deteriorate rapidly without appropriate treatment.

---

Complications

The spectrum of outcomes in acute cholangitis ranges from complete recovery with appropriate treatment to death from septic shock in the most severe, inadequately treated cases.

Mild Cholangitis

In patients with mild acute cholangitis, which is characterized by fever and abdominal pain without hemodynamic instability, altered mental status, or signs of multiorgan dysfunction, the prognosis with appropriate antibiotic therapy is excellent. Approximately 80–90% of mild cases respond well to antibiotics alone, with resolution of fever and improvement in laboratory parameters within 24–72 hours.

Moderate Cholangitis

Moderate cholangitis is characterized by early organ dysfunction that does not yet meet the criteria for severe disease. This category includes patients with:

• Abnormal white blood cell count (>12×10⁹/L or <4×10⁹/L)
• Fever above 39°C (102.2°F)
• Age ≥75 years
• Serum bilirubin ≥85.5 μmol/L (≥5 mg/dL)
• Albumin <0.7 × lower limit of normal

These patients require closer monitoring and more urgent biliary drainage if they do not respond promptly to initial antibiotic therapy.

Severe (Grade III) Cholangitis

Severe acute cholangitis is defined by the presence of dysfunction in one or more of the following organ systems:

• Cardiovascular: Hypotension requiring vasopressor therapy despite adequate fluid resuscitation
• Neurological: Altered level of consciousness
• Renal: Acute kidney injury (elevated creatinine, reduced urine output)
• Hepatic: Elevated bilirubin with features of hepatic dysfunction
• Hematological: Thrombocytopenia (platelet count <100×10⁹/L) and/or coagulopathy

Patients with severe cholangitis have a dramatically elevated risk of mortality. Without immediate intensive resuscitation and emergency biliary decompression, the mortality rate can reach 25–50%, primarily from:

• Sepsis and septic shock: The most common and most dangerous complication. Uncontrolled biliary infection seeds the bloodstream with bacteria and endotoxins, triggering a systemic inflammatory response that can cause cardiovascular collapse, multiorgan failure, and death.
• Multiorgan failure: Simultaneous failure of multiple organ systems (kidneys, lungs, liver, cardiovascular system, and brain) is the terminal pathway of untreated severe cholangitis.
• Liver abscess: Bacteria spreading from infected bile into the liver parenchyma can form a hepatic abscess, a walled-off collection of pus within the liver that requires drainage.
• Biliary peritonitis: Perforation of a markedly distended, infected bile duct or gallbladder into the peritoneal cavity, causing diffuse abdominal infection.

The Critical Role of Timing

The time from symptom onset to antibiotic administration and biliary decompression is one of the most powerful determinants of outcome in acute cholangitis. Studies consistently demonstrate that delays in initiating antibiotics and biliary drainage are associated with significantly worse outcomes, including higher rates of complications, longer hospital stays, and increased mortality. This is why acute cholangitis should always be treated as a medical emergency requiring urgent, not elective, evaluation and management.

---

Diagnosis

Clinical Assessment

The diagnosis of acute cholangitis begins with a thorough clinical history and physical examination. Key elements of the history include:

• Known cholelithiasis: Prior episodes of biliary colic, known gallstones, or prior biliary procedures significantly raise the probability of cholangitis.
• Recent cholecystectomy: Retained stones in the common bile duct after cholecystectomy are an important cause of post-operative cholangitis.
• Prior ERCP: ERCP itself can introduce bacteria into the biliary system and cause post-procedural cholangitis; biliary stents placed during prior ERCP may have occluded.
• Prior episodes of cholangitis: Recurrent cholangitis suggests an underlying structural biliary abnormality (stricture, recurring stones, tumor) requiring definitive management.
• HIV/AIDS and other causes of immunocompromise: Influence both susceptibility to cholangitis and the range of possible causative organisms.
• Travel history: Relevant for excluding parasitic biliary infection in returned travelers from endemic regions.

Physical examination typically reveals:

• Fever (>38°C / 100.4°F), often with rigors
• Jaundice (visible yellow discoloration of skin and sclera)
• Right upper quadrant tenderness: Pain on palpation of the right upper abdomen, sometimes with guarding (involuntary muscle tensing) and Murphy’s sign (pain and inspiratory arrest on deep palpation of the right upper quadrant)
• Hepatomegaly: Liver enlargement, sometimes palpable
• Signs of hemodynamic compromise in severe cases: Hypotension, tachycardia, diaphoresis

Diagnostic Criteria: Tokyo Guidelines

The Tokyo Guidelines (TG18/TG13), which are international evidence-based guidelines for the management of acute cholangitis and cholecystitis, provide a standardized diagnostic framework. According to the Tokyo Guidelines, acute cholangitis is diagnosed when the following criteria are met:

Diagnostic criteria for acute cholangitis (TG18):

• Suspected diagnosis: 1 item from A + 1 item from B or C
• Definitive diagnosis: 1 item from A + 1 item from B + 1 item from C

Laboratory Tests

Blood tests are essential both for confirming the diagnosis and for assessing disease severity:

• Complete Blood Count (CBC / Emocromo):

  • Leukocytosis (elevated WBC, typically >10–12×10⁹/L): Reflects the acute infectious process.
  • Leukopenia (very low WBC, <4×10⁹/L) in severe sepsis can indicate bone marrow suppression, a poor prognostic sign.
  • Thrombocytopenia: A marker of severe sepsis and DIC (disseminated intravascular coagulation).

• Liver function tests (LFTs):

  • Bilirubin (total, direct/conjugated, and indirect): Elevated, predominantly the direct (conjugated) fraction, in biliary obstruction. Levels correlate with the degree of obstruction.
  • Alkaline phosphatase (ALP) and GGT: Markedly elevated in cholestasis. The degree of ALP/GGT elevation is typically disproportionately greater than transaminase elevation in biliary disease.
  • Transaminases (ALT, AST): Variably elevated, reflecting hepatocyte injury from biliary back-pressure and ischemia. Extremely high transaminases (>10× normal) in acute cholangitis may indicate superimposed acute liver failure.
  • Albumin: Low in severe or prolonged disease; a marker of hepatic synthetic dysfunction and poor nutritional status.

• Inflammatory markers:

  • C-reactive protein (CRP): A highly sensitive acute-phase reactant that rises rapidly in infection and inflammation. Markedly elevated in acute cholangitis; levels correlate with disease severity.
  • Procalcitonin: A marker that rises specifically in bacterial infection and sepsis; elevated procalcitonin indicates bacterial etiology and correlates with bacteremia risk.
  • Erythrocyte sedimentation rate (ESR): Less specific but may be elevated.

• Coagulation profile:

  • Prothrombin time (PT/INR): May be prolonged in severe cholangitis from impaired hepatic synthesis of clotting factors and/or vitamin K deficiency (from fat malabsorption due to cholestasis). Significant coagulopathy requires correction before invasive procedures (ERCP, percutaneous drainage).

• Renal function and electrolytes:

  • Elevated creatinine and blood urea nitrogen (BUN) indicate acute kidney injury, an important complication and prognostic marker in severe cholangitis.
  • Electrolyte abnormalities (hyponatremia, hypokalemia) from vomiting and systemic illness require correction.

• Blood cultures:

  • Two sets of blood cultures (from different venipuncture sites) should be obtained before initiating antibiotic therapy in all patients with suspected acute cholangitis. Bacteremia is present in approximately 20–30% of cases, and in severe cholangitis, the rate is even higher.
  • Positive blood cultures identify the causative organism(s) and enable antibiotic de-escalation from broad-spectrum empiric coverage to targeted therapy once susceptibility results are available (typically 48–72 hours after culture).

Imaging Studies

Imaging is essential both to confirm the diagnosis of biliary obstruction and to identify the underlying cause and plan treatment.

Abdominal Ultrasound

Abdominal ultrasound is the recommended first-line imaging modality in suspected acute cholangitis. It is rapid, readily available, radiation-free, inexpensive, and highly informative for evaluating the biliary system:

• Biliary ductal dilatation: The hallmark finding of bile duct obstruction. A common bile duct diameter greater than 8 mm in a non-elderly patient (or greater than 10 mm in elderly patients or after cholecystectomy) is generally considered abnormal and indicative of obstruction.
• Gallstones: Ultrasound has excellent sensitivity (~95%) for detecting gallstones within the gallbladder. However, sensitivity for common bile duct (CBD) stones is lower (~50–75%), because the distal CBD is often obscured by bowel gas.
• Gallbladder wall thickening and distension: Markers of acute biliary disease.
• Pneumobilia (air in the bile ducts): May indicate prior biliary-enteric anastomosis, biliary-enteric fistula, or emphysematous cholangitis (a rare, extremely severe form caused by gas-producing organisms).
• Liver parenchymal abnormalities: Hepatic abscesses or hepatomegaly may be identified.

CT Scan (Computed Tomography)

Abdominal CT with intravenous contrast is valuable when:

• Ultrasound is inconclusive or technically inadequate (e.g., due to obesity or bowel gas overlying the bile ducts)
• A complication is suspected (hepatic abscess, perforation, peritonitis)
• An underlying malignancy (pancreatic cancer, cholangiocarcinoma) needs to be evaluated
• Differential diagnosis is needed to exclude other conditions that may mimic cholangitis, such as:
  • Diverticulitis: Left-sided abdominal pain and fever from colonic diverticular inflammation
  • Pyelonephritis: Kidney infection causing flank pain and fever
  • Peptic ulcer disease, pancreatitis, appendicitis, and other abdominal emergencies

CT also provides superior anatomical detail of the pancreas, lymph nodes, and surrounding structures, and can detect pneumobilia and hepatic abscesses with greater sensitivity than ultrasound.

Magnetic Resonance Cholangiopancreatography (MRCP)

MRCP (Magnetic Resonance Cholangiopancreatography) is the most sensitive non-invasive imaging technique for detecting:

• Common bile duct stones (sensitivity >95%)
• Biliary strictures
• The precise anatomical location and extent of biliary obstruction

MRCP generates detailed three-dimensional images of the entire biliary and pancreatic ductal system without radiation or contrast injection, using specialized MRI sequences. It is the imaging study of choice when:

• Ultrasound has not definitively identified CBD stones
• The cause of biliary obstruction is unclear
• A stricture (benign or malignant) is suspected
• ERCP is being planned and detailed biliary anatomy is needed

MRCP does not allow therapeutic intervention (unlike ERCP), but it provides superior diagnostic information for planning the most appropriate intervention.

ERCP (Endoscopic Retrograde Cholangiopancreatography)

ERCP is both the most sensitive diagnostic tool and the definitive therapeutic modality for acute cholangitis caused by common bile duct stones or strictures. ERCP combines endoscopy and fluoroscopy to directly visualize and access the biliary system through the ampulla of Vater.

In the context of acute cholangitis, ERCP allows:

1. Cholangiography: Direct injection of contrast into the bile duct to visualize and map the biliary anatomy, locate the obstruction, and identify stones or strictures.
2. Sphincterotomy: Surgical division of the sphincter of Oddi using electrocautery, opening the orifice of the bile duct to facilitate stone extraction and drainage.
3. Stone extraction: Removal of CBD stones using specialized balloons and baskets passed through the working channel of the endoscope.
4. Biliary stent placement: Placement of a plastic or metal stent across a stricture or above impacted stones to re-establish bile drainage. This is critically important in emergency settings when complete stone clearance is not immediately achievable.
5. Tissue sampling: Brush cytology and biopsies of strictures to evaluate for malignancy.
6. Culture collection: Bile can be aspirated during ERCP for microbiological culture, identifying causative organisms.

ERCP is particularly important in acute cholangitis because it uniquely combines diagnosis and treatment in a single procedure, identifying the cause of obstruction and immediately relieving it. This efficiency is critical in a condition where the speed of biliary decompression is a major determinant of outcome.

---

Treatment

The treatment of acute cholangitis has two simultaneous, equally essential objectives:

1. Control the biliary infection (with antibiotic therapy and supportive care)
2. Relieve the biliary obstruction (with biliary drainage)

The urgency with which each of these objectives must be pursued depends on the severity of the clinical presentation, as defined by the Tokyo Guidelines severity grading system.

Initial Resuscitation and Supportive Care

All patients with acute cholangitis require immediate:

• Intravenous access (one or preferably two large-bore peripheral IV cannulas)
• Fluid resuscitation: Intravenous crystalloid fluids (normal saline or lactated Ringer’s solution) to correct dehydration and maintain adequate organ perfusion. In hemodynamically compromised patients, aggressive fluid resuscitation is essential, targeting restoration of blood pressure and urine output.
• Vital sign monitoring: Continuous monitoring of heart rate, blood pressure, respiratory rate, oxygen saturation, and urine output (via urinary catheter in moderate-severe disease).
• Blood tests: Urgent laboratory panel as described above, including blood cultures before antibiotics.
• Analgesia: Adequate pain control, typically with intravenous opioids or non-steroidal anti-inflammatory drugs (NSAIDs) where not contraindicated.
• Intensive care unit (ICU) admission for patients with severe cholangitis, hemodynamic instability, altered mental status, or multiorgan dysfunction.

Antibiotic Therapy

Prompt initiation of intravenous antibiotics is one of the most critical interventions in acute cholangitis. Antibiotics should be started as soon as possible after blood cultures have been drawn, as any delay worsens outcomes. There should be no waiting for culture results before commencing empiric antibiotic therapy in a symptomatic patient.

Empiric antibiotic selection should provide broad-spectrum coverage against the most likely causative organisms (gram-negative enteric bacteria and enterococci), taking into account local antibiotic resistance patterns and patient-specific factors (allergy history, prior culture results, renal function):

First-line empiric antibiotic regimens for acute cholangitis:

• Fluoroquinolones (e.g., ciprofloxacin 400 mg IV every 12 hours): Excellent biliary penetration and broad gram-negative coverage. A first-line choice in many settings.
• Extended-spectrum penicillins with β-lactamase inhibitors (e.g., piperacillin-tazobactam 4.5 g IV every 6 hours): Broad-spectrum coverage including gram-negative organisms and anaerobes.
• Carbapenems (e.g., meropenem 1 g IV every 8 hours or imipenem-cilastatin): Reserved for severe disease, suspected ESBL-producing organisms, or prior antibiotic exposure. The most broad-spectrum option.
• Third-generation cephalosporins (e.g., ceftriaxone 2 g IV once daily) with metronidazole (500 mg IV every 8 hours, for anaerobic coverage): A practical combination offering good coverage of enteric organisms.
• Aminoglycosides (e.g., gentamicin): Used less frequently due to nephrotoxicity risk, particularly in the elderly. May be used in combination regimens.

Antibiotic therapy should be de-escalated to targeted, narrower-spectrum therapy as soon as culture and sensitivity results are available (typically 48–72 hours), reducing the risk of antibiotic resistance and side effects.

Duration of antibiotic therapy depends on the severity of illness and the success of biliary drainage:

• Mild-moderate cholangitis with successful drainage: 3–5 days of intravenous antibiotics, then oral completion (e.g., ciprofloxacin or amoxicillin-clavulanate) for a total of 5–7 days
• Severe cholangitis or bacteremia: Typically 10–14 days of total antibiotic therapy, with duration individualized based on clinical response

Biliary Drainage: The Cornerstone of Definitive Treatment

Antibiotic therapy alone is often insufficient to resolve acute cholangitis, particularly when biliary pressure is high and bacteria continue to proliferate in the obstructed system. Biliary drainage, which involves relieving the obstruction and allowing infected bile to drain, is frequently essential for a definitive cure.

Severity-Stratified Approach to Biliary Drainage (Tokyo Guidelines)

The Tokyo Guidelines recommend a severity-based approach to the timing and method of biliary drainage:

Grade I (Mild) Cholangitis:

• Most patients respond well to antibiotic therapy within 24–48 hours
• Biliary drainage is performed electively once the acute infectious episode is controlled
• ERCP for stone extraction is typically scheduled within 24–48 hours of presentation in patients who respond to antibiotics

Grade II (Moderate) Cholangitis:

• Early biliary drainage is recommended, typically within 24–48 hours of admission.
• If not responding to antibiotics within 24 hours, urgent drainage should be escalated.

Grade III (Severe) Cholangitis:

• Emergency biliary drainage is required as soon as the patient is hemodynamically stabilized enough to tolerate the procedure.
• Simultaneous ICU management of septic shock is required
• ERCP is the preferred modality; if not possible, percutaneous transhepatic biliary drainage (PTBD) is the alternative

ERCP with Biliary Drainage

ERCP is the preferred method of biliary drainage in the vast majority of cases of acute cholangitis. It is minimally invasive, highly effective, and allows simultaneous diagnosis and treatment. Key therapeutic interventions during ERCP for acute cholangitis include:

• Endoscopic sphincterotomy (ES): Division of the sphincter of Oddi to widen the bile duct orifice, facilitating stone passage and biliary drainage.
• Stone extraction: Removal of CBD stones using balloon catheters (which sweep stones from the duct into the duodenum) and dormia baskets. Large stones may require mechanical lithotripsy (fragmentation of the stone within the duct) or, in specialized centers, electrohydraulic lithotripsy or laser lithotripsy performed through a cholangioscope.
• Biliary stenting: When complete stone clearance is not achievable in an acutely ill patient (due to technical difficulty or patient instability), a plastic biliary stent is placed past the obstructing stone to ensure immediate bile drainage. Definitive stone clearance can then be achieved at a subsequent elective ERCP once the patient has recovered.
• Nasobiliary drainage tube: An alternative to stenting in some situations, a thin tube is passed through the papilla and externalized through the nose. This allows external bile drainage and repeat cholangiography without repeated endoscopy.

The success rate of ERCP for stone extraction in acute cholangitis is approximately 90–95% in experienced hands.

Percutaneous Transhepatic Biliary Drainage (PTBD)

PTBD (also called percutaneous transhepatic cholangiography and drainage, PTCD) is performed by an interventional radiologist under imaging guidance (ultrasound and fluoroscopy). A needle is inserted through the skin and liver parenchyma to puncture a dilated intrahepatic bile duct, through which a drainage catheter is placed to decompress the biliary system.

PTBD is indicated when:

• ERCP is technically not feasible due to altered anatomy from prior surgery, such as Billroth II gastrectomy or Roux-en-Y reconstruction, or prior failed ERCP.
• The obstruction is at the hepatic hilum or intrahepatic bile ducts and is not accessible from the endoscopic (ampullary) approach.
• As a bridge to surgery in patients with malignant biliary obstruction

PTBD can be performed under sedation, without general anesthesia, making it suitable for critically ill patients who cannot tolerate ERCP.

Surgical Biliary Drainage

Surgical drainage via open or laparoscopic common bile duct exploration is now reserved for situations where ERCP and PTBD have both failed or are unavailable. With the widespread availability of endoscopic and radiological intervention, emergency surgery for acute cholangitis is uncommon but remains an important option of last resort. Surgical intervention has higher morbidity and mortality than endoscopic or radiological drainage, particularly in critically ill patients.

Definitive Treatment of the Underlying Cause

Once the acute episode of cholangitis has been resolved with antibiotics and biliary drainage, the underlying cause of biliary obstruction must be addressed to prevent recurrence:

• Cholelithiasis (gallstones): After successful ERCP with CBD stone clearance, laparoscopic cholecystectomy (surgical removal of the gallbladder) is recommended in most patients to prevent recurrent biliary colic and cholangitis. Cholecystectomy is typically scheduled within a few weeks of the cholangitis episode, once the patient has fully recovered.

• Malignant biliary obstruction: Patients with cholangiocarcinoma or pancreatic cancer causing biliary obstruction may require surgical resection (if the tumor is operable), palliative biliary stenting (for unresectable disease), or a combination of chemoradiation and stenting.

• Biliary strictures: Benign strictures (from prior surgery or PSC) can be managed with endoscopic balloon dilatation and stenting, or surgical biliary reconstruction (hepaticojejunostomy) in cases of recurrent or complex strictures.

• Biliary stent occlusion: Occluded stents require endoscopic exchange (replacement with a new stent). In patients with malignant biliary obstruction managed by palliative stenting, regular stent surveillance and planned exchange every 3–6 months (for plastic stents) or when clinically indicated (for covered metal stents) can reduce the frequency of stent-related cholangitis.

---

Sources and Bibliography

• Virgile J, Marathi R. Cholangitis. StatPearls, National Center for Biotechnology Information (NCBI). Updated 2023.
• Johns Hopkins Medicine - Cholangitis
• Kiriyama S, Kozaka K, Takada T, et al. “Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholangitis (with videos)”. Journal of Hepato-Biliary-Pancreatic Sciences. 2018;25(1):17–30.
• Miura F, Okamoto K, Takada T, et al. “Tokyo Guidelines 2018: initial management of acute biliary infection and flowchart for acute cholangitis”. Journal of Hepato-Biliary-Pancreatic Sciences. 2018;25(1):31–40.
• Gomi H, Solomkin JS, Schlossberg D, et al. “Tokyo Guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis”. Journal of Hepato-Biliary-Pancreatic Sciences. 2018;25(1):3–16.
• Lee JG. “Diagnosis and management of acute cholangitis”. Nature Reviews Gastroenterology & Hepatology. 2009;6(9):533–541.
• Lipsett PA, Pitt HA. “Acute cholangitis”. Surgical Clinics of North America. 1990;70(6):1297–1312.
• European Association for the Study of the Liver (EASL). “EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones”. Journal of Hepatology. 2016;65(1):146–181.
• Wada K, Takada T, Kawarada Y, et al. “Diagnostic criteria and severity assessment of acute cholangitis: Tokyo Guidelines”. Journal of Hepato-Biliary-Pancreatic Sciences. 2007;14(1):52–58.